Schering-Plough

Bruno Ultra BARCELOS is appointed Managing Director of Ethypharm UK

Retrieved on: 
Tuesday, January 31, 2023
Safety, Manager, Teva Pharmaceuticals, Marketing, Schering-Plough, Fine chemical, Novartis

SAINT-CLOUD, France, Jan. 31, 2023 /PRNewswire/ -- The Ethypharm Group appoints Bruno Ultra BARCELOS as Managing Director of its UK subsidiary.

Key Points: 
  • SAINT-CLOUD, France, Jan. 31, 2023 /PRNewswire/ -- The Ethypharm Group appoints Bruno Ultra BARCELOS as Managing Director of its UK subsidiary.
  • Bruno Ultra BARCELOS holds an Executive MBA from Kellogg-WHU He has 30 years of experience in Europe with large international pharmaceutical groups, specialising in both specialities, biosimilars and generic medicines (Schering-Plough, Teva Pharmaceuticals, Novartis Group).
  • Bruno Ultra BARCELOS joins the Ethypharm Group as Managing Director of the Ethypharm UK subsidiary, Ethypharm's first commercial affiliate, representing 30% of its turnover.
  • As Managing Director of Ethypharm UK I will continue to foster a growth mindset and focus the teams on the opportunities ahead.

Advarra Announces Appointments of Scott Hoffman as Chief Commercial Officer and Scott Uebele as Chief Operating Officer

Retrieved on: 
Wednesday, January 25, 2023
ChromeOS, HCLTech, IRB, Michael Uebel, Growth, State Street Bank and Trust Company, Schering-Plough, Consultant, Sanofi, Research, IBC, Senior, Medidata Solutions, Management, Nursing

COLUMBIA, Md., Jan. 25, 2023 /PRNewswire/ -- Advarra, the market leader in regulatory review solutions, clinical research technology for sites and sponsors, and research quality and compliance consulting services, announced today that Scott Hoffman has joined the company as Chief Commercial Officer. In addition, Scott Uebele, formerly President & Chief Research Services Officer at Advarra, has been promoted to the newly created role of Chief Operating Officer. These leadership appointments reinforce the company's focus on advancing clinical research through integrated solutions for sites, sponsors, and CROs and underscore Advarra's commitment to operational excellence.

Key Points: 
  • In addition, Scott Uebele, formerly President & Chief Research Services Officer at Advarra, has been promoted to the newly created role of Chief Operating Officer.
  • Hoffman will be responsible for managing the commercial organization and driving a unified, client-centric commercial strategy.
  • Previously, Uebele held the position of Chief Financial Officer at Advarra where he directed the financial, legal, analytics, and contracts activities.
  • "Scott Uebele is a great fit for the newly created role of Chief Operating Officer," said Saarony.

Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader

Retrieved on: 
Tuesday, January 17, 2023
Medical Supplies, Health, Research, Pharmaceutical, Science, Biotechnology, Bristol Myers Squibb, AMAG Pharmaceuticals, API, Avon Products, CTLT, Senior, NYSE, Sterling Drug, Warner–Lambert, Patient, Engineering, Kansas State University, Product strategy, Schering-Plough, Multimedia, Supply chain, Management, Pharmaceutical industry, Catalent, Pfizer, Operation

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America.

Key Points: 
  • Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America.
  • Mr. Zayas will be responsible for all of the company’s North American biologics operations, including its centers of excellence for drug product fill/finish in Bloomington, Indiana, and gene therapy manufacturing in Harmans, Maryland.
  • He will serve on the Executive Leadership Team, reporting directly to Catalent’s President & Chief Executive Officer, Alessandro Maselli.
  • View the full release here: https://www.businesswire.com/news/home/20230117005260/en/
    Ricardo Zayas, who joins Catalent as Senior Vice President, Operations, Biologics North America.

EVOQ Therapeutics Expands Leadership Team with David Giljohann, Ph.D., as Chief Executive Officer and Greg Barrett as Chief Operating Officer

Retrieved on: 
Monday, January 9, 2023
Nanodisc, International, Biotechnology, Therapy, Crain's Chicago Business, DNA, Champaign County, Illinois, Nanoparticle, Patient, Cardiovascular disease, Degenerative disease, Schering-Plough, Barrett, University, Hypertension, SNA, ANN, Arbutus Biopharma, Pharmaceutical industry, Northwestern University, Biochemistry

The company also announced the appointment of Greg Barrett as Chief Operating Officer.

Key Points: 
  • The company also announced the appointment of Greg Barrett as Chief Operating Officer.
  • "The pre-clinical efficacy demonstrated in multiple autoimmune diseases underscores the potential of EVOQ's transformative immunotherapies," David Giljohann said.
  • "On behalf of everyone at EVOQ, we are honored to welcome David and Greg to our team."
  • Most recently, he served as Chief Executive Officer of Exicure where he led the company in developing spherical nucleic acid (SNA) constructs.

The Alliance for Regenerative Medicine Appoints Mark Battaglini as Chief Strategy Officer

Retrieved on: 
Tuesday, January 3, 2023
Government, Pharmacia, American Society of Gene and Cell Therapy, Regenerative medicine, Bluebird bio, Bluebird, Cell therapy, Gene, Organization, Patient, Public policy, Medicine, Amylin Pharmaceuticals, Cubist Pharmaceuticals, ARM, Senior, Society, Schering-Plough, Pharmaceutical industry

Washington, D.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the cell and gene therapy sector, announced the appointment of Mark Battaglini to the newly created position of Chief Strategy Officer, effective today.

Key Points: 
  • Washington, D.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the cell and gene therapy sector, announced the appointment of Mark Battaglini to the newly created position of Chief Strategy Officer, effective today.
  • Mr. Battaglini will be responsible for ARM’s global policy, government affairs, communications, and alliance development activities.
  • He will also lead the development of ARM’s strategy, mission, and vision, and guide the execution of the organization’s major priorities.
  • “I am honored for the opportunity to serve as ARM’s Chief Strategy Officer,” said Mr. Battaglini.

Winston Weber is recognized by Continental Who's Who

Retrieved on: 
Friday, January 6, 2023
General Foods, Pinnacle, Organization, Food Marketing Institute, Business consultant, Multimedia, Winston, Fortune Brands (1969–2011), Colgate-Palmolive, Atari, Rathinam College of Arts and Science, Associate, Schering-Plough, Trust, College, Syracuse University, Senior, Continental, Sunshine Biscuits, Management

TAMPA, Fla., Jan. 6, 2023 /PRNewswire/ -- Winston Weber is being recognized by Continental Who's Who as an Top Pinnacle Executive in the Business Consulting field and for his contributions at Winston Weber & Associates.

Key Points: 
  • TAMPA, Fla., Jan. 6, 2023 /PRNewswire/ -- Winston Weber is being recognized by Continental Who's Who as an Top Pinnacle Executive in the Business Consulting field and for his contributions at Winston Weber & Associates.
  • Mr. Weber is the Chairman, Chief Executive Officer, and Founder of Winston Weber & Associates since 1985.
  • According to Mr. Weber, His company is the leader in retail strategy consulting, Winston Weber & Associates is a pioneer in retail growth maximization and shopper centricity.
  • Winston Weber & Associates is known for a thorough and uncompromising emphasis on quality and trust and employs a "say it as we see it" approach.

Eiger BioPharmaceuticals Announces Leadership Change

Retrieved on: 
Thursday, December 15, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Bristol Myers Squibb, Schering-Plough, FDA, Progeria, Eiger, Biotechnology, Biopharmaceutical, Hepatitis, Doctor of Philosophy, MD, Risk, MBA, Investment, HDV, Degenerative disease, Compte rendu, Patient, Management, Pharmaceutical industry

Following his departure from that position, he has been serving as a Director, Senior Clinical Advisor and board member at Eiger.

Key Points: 
  • Following his departure from that position, he has been serving as a Director, Senior Clinical Advisor and board member at Eiger.
  • Im proud to have been a part of a great team and look forward to seeing future successes at Eiger.
  • Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for HDV and other serious rare diseases.
  • The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication.

Wren Taps Vertex Veteran Executives and Other Leaders to Advance First-in-Class Small-Molecule Drugs into Clinical Testing for Neurodegenerative Diseases

Retrieved on: 
Thursday, December 8, 2022
Novartis Institute for Tropical Diseases, Therapy, Degenerative disease, Friedreich's ataxia, Neurodegeneration, Thomson, Biomedical Research, Agios Pharmaceuticals, NDA, Alzheimer's disease, Sickle cell disease, Doctor of Philosophy, Drug discovery, Biophysics, Research, Hepatitis, Science, Ideation, IEEE Corporate Innovation Recognition, Schering-Plough, Autism, Vertex, Huntington's disease, FDA, Drug development, Pharmaceutical Development and Technology, ALS, NIBR, Endocrinology, Vertex Pharmaceuticals, Human, Translation, Senior, Connelly, Head, Hepatitis C, Inflammation, Parkinson's disease, Decibel, Cystic fibrosis, Ipsen, Fine chemical, Pharmaceutical industry, Management, Chemistry, Wren, Ivosidenib, EU, Sanofi, DRS

BOSTON, Dec. 8, 2022 /PRNewswire/ -- Wren Therapeutics announced today a number of senior leadership appointments as the company advances its first investigational therapies toward the clinic, based on the company's breakthrough approach to discovering small molecules that precisely target and shut down the sources of oligomer and aggregate generation in neurodegenerative diseases.

Key Points: 
  • The company recently welcomed Vertex Pharmaceuticals veterans John Thomson, PhD and Patrick Connelly, PhD as its Chief Scientific Officer and first Chief Innovation Officer, respectively.
  • Dr. Thomson and Dr. Connelly are Vertex founding scientists who worked together on leadership teams that discovered and developed Vertex's seven FDA-approved drugs.
  • "We couldn't be more pleased to welcome John, Pat, Mike, Janeta, and Rajeev to Wren's teamall proven executives in their fields.
  • With this lineup of experienced talent, Wren has the leadership team to break open the field of neurodegenerative diseases targeting the molecular mechanisms at the source of toxic oligomer generation."

The North American Veterinary Community Partners with Veterinary Industry Leader in DEI to Inspire and Support Future Veterinarians

Retrieved on: 
Tuesday, December 6, 2022
Sentinel, ER, Publication, Schering-Plough, Hill, Intubation, National Geographic, Veterinarian, Person, Parent, VMX, Boehringer Ingelheim Animal Health, Life, Partnership, DEI, Hill's Pet Nutrition, Animal, Banfield Pet Hospital, BIPOC, American Veterinary Medical Association, Orange County Convention Center, MLK, Mentorship, Orlando Sentinel, Student, Emergency medicine, Multimedia, Education, Dermatology, Veterinary medicine, Vet, Sentinel (comics), Tutoring, Medicine, Central Florida

ORLANDO, Fla., Dec. 6, 2022 /PRNewswire/ -- The North American Veterinary Community (NAVC) is proud to announce its partnership with the nationally-recognized DEI BLEND program to provide inspiration, education and scholarship support to enable underserved middle school-aged children to pursue a career in veterinary medicine. The immersive, hands-on educational program will debut with a diversity-focused event on Martin Luther King Jr. Day for minority students from Central Florida during the 2023 Veterinary Meeting & Expo (VMX). VMX is the world's leading annual veterinary conference. It will be hosted in Orlando from Jan. 14 to 18 at the Orange County Convention Center. The event, "A Day of Service: Believe & Belong in Veterinary Medicine," is sponsored by Banfield Pet Hospital, Boehringer Ingelheim Animal Health, Hill's Pet Nutrition and Merck Animal Health.

Key Points: 
  • "We are passionate about providing ongoing education and mentoring to the veterinarians of tomorrow through our new initiative," said NAVC CEO Gene O'Neill.
  • "A Day of Service: Believe & Belong in Veterinary Medicine" will be led by BLEND's founder and CEO, Dr. Niccole Bruno.
  • Participating students will learn about the various aspects of veterinary medicine from a diverse group of veterinary experts at VMX 2023.
  • Activities planned for students include:
    Hands-on experience using workshop stations to learn about veterinary surgery, dermatology, emergency medicine and preventive care.

Chemomab Announces Appointment of Matthew Frankel, MD, MBA as Chief Medical Officer

Retrieved on: 
Monday, November 14, 2022
Biosimilar, Conditional sentence, Doctor of Philosophy, Primary sclerosing cholangitis, SEC, Peripheral nervous system, Cirrhosis, Lasso, Drug development, MD, Therapy, Forward-looking statement, MBA, Boehringer Ingelheim, Dermatology, University, Risk, Everolimus, Fibrosis, Marketing, Research, TEL, Internal medicine, Private Securities Litigation Reform Act, Patient, Northwestern University, Vassar College, Abbott Laboratories, Inflammation, Nature, Communication, CMMB, Medical Affairs Bureau, CMO, CCL24, Senior advisor, Schering-Plough, Pharmaceutical industry, Novartis

TEL AVIV, Israel, Nov. 14, 2022 /PRNewswire/ --Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Matthew Frankel, MD, MBA as Chief Medical Officer (CMO) and Vice President of Drug Development.

Key Points: 
  • TEL AVIV, Israel, Nov. 14, 2022 /PRNewswire/ --Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Matthew Frankel, MD, MBA as Chief Medical Officer (CMO) and Vice President of Drug Development.
  • Previously Dr. Frankel was Vice President & Head, Immunology and Dermatology Medical Unit at Novartis, where he oversaw medical affairs activities and late phase clinical development for Cosentyx, Ilaris, and Zortress.
  • Chemomab is a clinical stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need.
  • Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements.